Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2019 Filed Mar 2, 2019 01:19 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 40,000 | $22.69 | $907,600.00 |
DisclosureSEC source: 0000939767-19-000056 · wf-form4_155148957562576.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.08 to $22.98. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 27, 2019 Filed Mar 2, 2019 01:19 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000056 · wf-form4_155148957562576.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:30 UTC |
COHEN CHARLESDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000052 · wf-form4_155131741145981.xml · derivative · entry 5 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:30 UTC |
COHEN CHARLESDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000052 · wf-form4_155131741145981.xml · derivative · entry 4 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:30 UTC |
COHEN CHARLESDirector
|
SaleCommon Stock | 5,271 | $22.18 | $116,910.78 |
DisclosureSEC source: 0000939767-19-000052 · wf-form4_155131741145981.xml · nonDerivative · entry 3 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,979 Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:30 UTC |
COHEN CHARLESDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000052 · wf-form4_155131741145981.xml · nonDerivative · entry 2 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:30 UTC |
COHEN CHARLESDirector
|
Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000052 · wf-form4_155131741145981.xml · nonDerivative · entry 1 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Feb 28, 2019 01:28 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 4,272 | $22.27 | $95,137.44 |
DisclosureSEC source: 0000939767-19-000051 · wf-form4_155131731710571.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,739 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.27 to $22.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · derivative · entry 7 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · derivative · entry 6 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · derivative · entry 5 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
SaleCommon Stock | 41,250 | $21.50 | $886,875.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · nonDerivative · entry 4 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,850 Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · nonDerivative · entry 3 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
Exercise / conversionCommon Stock | 15,000 | $5.92 | $88,800.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · nonDerivative · entry 2 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:32 UTC |
MARCHESI VINCENT TDirector
|
Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000046 · wf-form4_155088191775816.xml · nonDerivative · entry 1 MARCHESI VINCENT T · CIK 0001202095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:35 UTC |
PAPADOPOULOS STELIOSDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000048 · wf-form4_155088213177229.xml · derivative · entry 5 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:35 UTC |
PAPADOPOULOS STELIOSDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000048 · wf-form4_155088213177229.xml · derivative · entry 4 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:35 UTC |
PAPADOPOULOS STELIOSDirector
|
SaleCommon Stock | 26,250 | $21.25 | $557,812.50 |
DisclosureSEC source: 0000939767-19-000048 · wf-form4_155088213177229.xml · nonDerivative · entry 3 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,042,251 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.24 to $21.28. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:35 UTC |
PAPADOPOULOS STELIOSDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000048 · wf-form4_155088213177229.xml · nonDerivative · entry 2 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,068,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:35 UTC |
PAPADOPOULOS STELIOSDirector
|
Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000048 · wf-form4_155088213177229.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,937 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 20, 2019 Filed Feb 23, 2019 00:33 UTC |
WILLSEY LANCEDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000047 · wf-form4_155088200783323.xml · derivative · entry 5 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| February 20, 2019 Filed Feb 23, 2019 00:33 UTC |
WILLSEY LANCEDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-19-000047 · wf-form4_155088200783323.xml · derivative · entry 4 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| February 20, 2019 Filed Feb 23, 2019 00:33 UTC |
WILLSEY LANCEDirector
|
SaleCommon Stock | 26,250 | $21.11 | $554,137.50 |
DisclosureSEC source: 0000939767-19-000047 · wf-form4_155088200783323.xml · nonDerivative · entry 3 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,273 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.10 to $21.16. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| February 20, 2019 Filed Feb 23, 2019 00:33 UTC |
WILLSEY LANCEDirector
|
Exercise / conversionCommon Stock | 15,000 | $4.57 | $68,550.00 |
DisclosureSEC source: 0000939767-19-000047 · wf-form4_155088200783323.xml · nonDerivative · entry 2 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2019 Filed Feb 23, 2019 00:33 UTC |
WILLSEY LANCEDirector
|
Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-19-000047 · wf-form4_155088200783323.xml · nonDerivative · entry 1 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 01:10 UTC |
COHEN CHARLESDirector
|
SaleCommon Stock | 48,180 | $21.48 | $1,034,906.40 |
DisclosureSEC source: 0000939767-19-000031 · wf-form4_155062501418461.xml · nonDerivative · entry 3 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.22 to $22.11. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:11 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 23,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · derivative · entry 7 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:11 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 23,000 | $22.20 | $510,600.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:11 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 23,000 | $5.56 | $127,880.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
GiftCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · nonDerivative · entry 5 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,521 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 01:10 UTC |
COHEN CHARLESDirector
|
SaleCommon Stock | 100,000 | $22.19 | $2,219,000.00 |
DisclosureSEC source: 0000939767-19-000031 · wf-form4_155062501418461.xml · nonDerivative · entry 2 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,180 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.02 to $22.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · derivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 200 | $22.66 | $4,532.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.65 to $22.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 39,800 | $22.39 | $891,122.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,200 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.65 to $22.62. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 40,000 | $5.56 | $222,400.00 |
DisclosureSEC source: 0000939767-19-000029 · wf-form4_155027966347277.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 90,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:11 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · derivative · entry 6 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 100,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 123,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:11 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 100,000 | $21.66 | $2,166,000.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,513 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.39 to $22.02 Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:11 UTC |
Schwab GiselaPres, Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 100,000 | $5.56 | $556,000.00 |
DisclosureSEC source: 0000939767-19-000027 · wf-form4_155027943888006.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres, Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionOption (right to buy) · Derivative | 24,000 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · derivative · entry 8 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 24,000 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 30,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 23, 2013. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,500 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · derivative · entry 7 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2019-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 24, 2012. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.92 | $0.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · derivative · entry 6 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2010. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
SaleCommon Stock | 50,500 | $22.03 | $1,112,515.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · nonDerivative · entry 4 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,221 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.01 to $22.08. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionCommon Stock | 24,000 | $4.58 | $109,920.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · nonDerivative · entry 3 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionCommon Stock | 11,500 | $4.57 | $52,555.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · nonDerivative · entry 2 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 16, 2019 01:06 UTC |
FELDBAUM CARL BDirector
|
Exercise / conversionCommon Stock | 15,000 | $5.92 | $88,800.00 |
DisclosureSEC source: 0000939767-19-000025 · wf-form4_155027915849687.xml · nonDerivative · entry 1 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 20, 2019 01:10 UTC |
COHEN CHARLESDirector
|
SaleCommon Stock | 100,000 | $22.41 | $2,241,000.00 |
DisclosureSEC source: 0000939767-19-000031 · wf-form4_155062501418461.xml · nonDerivative · entry 1 COHEN CHARLES · CIK 0001202089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,180 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.27 to $22.65. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 01:36 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 1,000 | $21.30 | $21,300.00 |
DisclosureSEC source: 0000939767-19-000023 · wf-form4_155010817906342.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,011 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 23, 2018. F2 · balance_after: Includes 49,234 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 01:03 UTC |
SCANGOS GEORGE ADirector
|
SaleCommon Stock | 40,000 | $23.53 | $941,200.00 |
DisclosureSEC source: 0000939767-19-000018 · wf-form4_154906938797191.xml · nonDerivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,031 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2018. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.43 to $23.66. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:58 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock · Derivative | 40,000 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0000939767-19-000016 · wf-form4_154906911161318.xml · derivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,000 Underlying: Common Stock · 40,000 shares Expires 2019-09-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 402,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 21, 2016. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:58 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 40,000 | $23.12 | $924,800.00 |
DisclosureSEC source: 0000939767-19-000016 · wf-form4_154906911161318.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 29, 2018. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.81 to $23.33. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.